ANXA114-26: A Peptide That Helps Fight Ovarian Cancer
Author Information
Author(s): Nana Li, Peihua Yan, Guo Ling, Wang Huiyan, Cui Baohong, Teng Lichen, Su Yajuan
Primary Institution: Harbin Medical University Cancer Hospital
Hypothesis
ANXA114-26 inhibits ovarian cancer cell proliferation and reverses cisplatin resistance by binding to FPR receptors.
Conclusion
ANXA114-26 can inhibit the proliferation of ovarian cancer cells and reduce drug resistance to cisplatin.
Supporting Evidence
- ANXA114-26 was found to be highly expressed in the serums of sensitive ovarian cancer patients.
- ANXA114-26 promoted apoptosis of ovarian cancer cells.
- ANXA114-26 decreased MRP1 expression in ovarian cancer cells.
- ANXA114-26 can inhibit the proliferation of SKOV3 and SKOV3/DDP cells.
Takeaway
A small peptide called ANXA114-26 can help make ovarian cancer cells more sensitive to treatment by stopping them from growing and fighting off the medicine.
Methodology
The study used iTRAQ technology, CCK-8 assays, EdU assays, Annexin V-FITC/PI assays, Western blotting, and qRT-PCR to analyze the effects of ANXA114-26 on ovarian cancer cells.
Statistical Information
P-Value
0.040350765
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website